Ascletis slashes funding for former core programs in pivot to obesity
Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease clinical trials while rapidly retreating from the antiviral, oncology and liver programs that were once at the heart of its strategy.
Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease clinical trials while rapidly retreating from the antiviral, oncology and liver programs that were once at the heart of its strategy.
